Advances in Longevity Research

Ageing and Science

For most of human history, ageing was treated as an inevitable decline — something that simply happened to you, like weather. The science of the past thirty years has dismantled that assumption. Ageing is now understood as a biological process driven by specific, identifiable mechanisms. And if it's a process rather than a fate, it can, in principle, be slowed, modified, and in some respects reversed.

This shift in thinking is not fringe science. It sits at the centre of some of the most well-funded research programmes in the world, involving Nobel laureates, major universities, and a generation of molecular biologists who grew up treating ageing as a legitimate target rather than a given. Understanding what they've found — and what it means for how you live now — is the point of this page.

Longevity Research

From Lab to Life: What's Ready Now, What's Coming, What's Still Unproven

Longevity research moves fast — and the gap between genuine breakthrough and inflated claim is wide. This tracker maps the major intervention areas by where they actually sit on the readiness spectrum, not where enthusiasts say they are.

Available now

Strong evidence, accessible today

Epigenetic age testing

Clocks like DunedinPACE and GrimAge measure biological age from a blood or saliva sample with meaningful predictive accuracy for disease risk and mortality. Several commercial tests now use validated algorithms. Useful as a baseline and for tracking the impact of lifestyle changes over 6–12 month intervals. Not a substitute for clinical markers, but a genuinely informative addition.

Metformin (off-label longevity use)

The most widely prescribed diabetes drug has significant epidemiological data showing lower all-cause mortality and cancer rates in diabetic patients compared with other treatments — and even, in some analyses, compared with non-diabetic controls. It activates AMPK and reduces mTOR signalling. The landmark TAME trial (Targeting Aging with Metformin) is now underway specifically to test it in non-diabetic older adults. Many longevity-focused clinicians already prescribe it off-label.

Comprehensive biomarker panels

Beyond standard NHS bloods: ApoB, Lp(a), fasting insulin, HOMA-IR, hsCRP, homocysteine, ferritin, vitamin D, and HbA1c together give a far more complete picture of metabolic and cardiovascular risk than routine panels. These are available privately and increasingly through forward-thinking GPs. Acting on them — not just testing — is where the value lies.

Early clinical

Promising, but watch carefully

Senolytics (dasatinib + quercetin, fisetin)

Drugs that selectively clear senescent cells have produced striking results in animal models — reversing multiple markers of age-related decline. Human trials are now underway for specific conditions including pulmonary fibrosis, diabetic kidney disease, and frailty. Early Phase 1/2 results are cautiously positive. Not yet approved for longevity use, but fisetin (a natural senolytic) is widely available as a supplement. Human efficacy data is still limited.

Rapamycin (mTOR inhibition)

The most consistent life-extension result across multiple animal species. Inhibits mTOR, pushing cells toward repair rather than growth. Used clinically as an immunosuppressant after organ transplant. Intermittent low-dose protocols are increasingly used off-label by longevity physicians, with the hypothesis that cycling avoids immune suppression while preserving mTOR benefits. No randomised human longevity trial has completed yet.

GLP-1 agonists (semaglutide, tirzepatide)

Originally developed for diabetes, these drugs have shown cardiovascular mortality reduction in large trials — and emerging data suggests anti-inflammatory and neuroprotective effects beyond weight loss. The SELECT trial showed 20% reduction in major cardiovascular events in non-diabetic obese patients. Whether benefits persist at lower doses or in leaner individuals is actively being studied. Currently approved for specific indications; longevity use is broader than current licensing.

Experimental

Compelling science, human evidence still early

Epigenetic reprogramming

Partial reprogramming using Yamanaka factors (or subsets of them) has reversed epigenetic age in animal cells and tissues — including restoring vision in aged mice. David Sinclair's lab and several biotech companies (Altos Labs, NewLimit, Turn Biotechnologies) are racing to translate this to humans. The central challenge is achieving tissue-specific rejuvenation without triggering tumour formation. Timeline to human application: uncertain, but active.

Young plasma / parabiosis-derived factors

Connecting the circulatory systems of old and young mice (parabiosis) rejuvenated multiple tissues in the older animal. Research has shifted toward identifying specific circulating factors — proteins like GDF11, TIMP2, and clusterin — that mediate these effects. Human trials of plasma fractions have produced mixed and contested results. The science is real; the translation is far from settled.

CRISPR-based longevity gene editing

Editing longevity-associated genes — FOXO3, APOE, PCSK9 — is technically feasible and being actively explored. Single-base editing of PCSK9 to permanently lower LDL is in early human trials for cardiovascular prevention. Broad longevity gene editing in healthy humans remains distant — delivery, off-target effects, and regulatory pathways are all unsolved. But targeted cardiovascular applications are moving faster than most people realise.

The Honest Context

→ No drug or therapy currently available extends healthy human lifespan with the reliability of consistent exercise, good sleep, and a well-structured diet. → The most exciting interventions — senolytics, rapamycin, reprogramming — are being tested in people who are already optimising lifestyle. They are likely to be additions to, not substitutes for, the fundamentals. → The readiness pipeline moves faster than headlines suggest in some areas (GLP-1s, biomarker testing) and slower in others (reprogramming, gene editing). Healthy scepticism, not dismissal, is the right default.

The hallmarks of ageing

In 2013, a landmark paper by López-Otín and colleagues identified nine hallmarks of ageing — the core biological processes that drive cellular and organismal decline. The list has since been expanded to twelve. These aren't competing theories. They're interconnected mechanisms that reinforce each other, and understanding them changes how you think about everything from exercise to diet to sleep.

Telomere shortening is perhaps the best-known mechanism. Every time a cell divides, the protective caps on the ends of chromosomes — telomeres — lose a small amount of length. When they shorten beyond a critical point, the cell can no longer divide safely. It either dies or enters senescence. Telomere length is now used as one measure of biological age, and the rate of shortening is significantly affected by lifestyle: chronic stress, poor sleep, and smoking all accelerate it, while exercise, omega-3 supplementation, and stress reduction appear to slow it.

Cellular senescence is closely related but distinct. Senescent cells are cells that have stopped dividing but haven't died. They accumulate with age and release a cocktail of inflammatory signals — the senescence-associated secretory phenotype, or SASP — that damages surrounding tissue, drives chronic inflammation, and disrupts normal organ function. A small number of senescent cells can cause disproportionate harm. Drugs called senolytics, which selectively clear senescent cells, have produced dramatic results in animal studies and are now entering human trials.

Mitochondrial dysfunction is one of the less visible but most consequential hallmarks. Mitochondria — the organelles that produce cellular energy — become less efficient with age, generating more oxidative by-products and less ATP. The result is a progressive energy deficit at the cellular level that shows up as fatigue, muscle weakness, and reduced organ function. Exercise is the most effective known intervention for maintaining mitochondrial health — it directly stimulates the production of new mitochondria through a process called mitogenesis.

Epigenetic alterations represent one of the most exciting recent developments. The epigenome is the system of chemical tags on DNA that controls which genes are expressed. These tags change with age in predictable patterns — so predictable that epigenetic clocks can now estimate biological age with remarkable accuracy, often more accurately than chronological age. David Sinclair at Harvard has argued that ageing is fundamentally an epigenetic phenomenon — a loss of cellular identity information rather than accumulated DNA damage — and that restoring epigenetic patterns might be the most direct route to reversing biological ageing.

Inflammaging — the chronic, low-grade inflammation that characterises aged tissue — underlies nearly every major age-related disease. It's not the acute inflammation of injury or infection, which resolves quickly and serves a purpose. It's a persistent background hum of inflammatory signalling that drives cardiovascular disease, neurodegeneration, metabolic dysfunction, and cancer. The accumulation of senescent cells is one driver. Others include gut microbiome changes, increased intestinal permeability, and the chronic activation of innate immune sensors by cellular debris.

What lifestyle does to these mechanisms

This is where the science becomes practically useful. Each of the hallmarks is modifiable to some degree by lifestyle, and the same interventions — exercise, sleep, diet, stress management — consistently appear across multiple mechanisms simultaneously.

Exercise acts on at least six of the twelve hallmarks directly. It stimulates mitogenesis, reduces senescent cell accumulation, improves epigenetic markers, reduces inflammaging, supports stem cell function, and maintains proteostasis — the cellular system for managing protein quality. No pharmaceutical intervention comes close to this breadth of effect. The dose-response curve is steep at the low end: going from sedentary to moderately active produces larger biological benefits than going from moderately active to highly trained.

Caloric restriction — reducing energy intake without malnutrition — is the most consistently replicated longevity intervention in animal studies, extending healthy lifespan across a remarkable range of species. The mechanism involves activation of AMPK and sirtuins, proteins that sense nutrient availability and upregulate cellular maintenance and repair when resources are scarce. In humans, the evidence for dramatic lifespan extension is less clear, but the metabolic and inflammatory benefits of moderate caloric restriction are well-established. Time-restricted eating appears to activate some of the same pathways without requiring chronic caloric deficit.

Sleep is when several of the most critical cellular maintenance processes run at full capacity. DNA repair, glymphatic clearance of neurotoxic proteins, immune surveillance, and epigenetic restoration all peak during deep sleep. Chronic sleep deprivation is now understood not just as a performance issue but as a direct accelerant of biological ageing — measurably shortening telomeres and elevating inflammatory markers.

Free guide

The Longer Life Manual

What the evidence actually says about living longer and better.

Get the free manual

The frontier: can ageing be reversed?

The most provocative recent development is not slowing ageing but reversing it. Yamanaka factors — the four transcription factors that can reprogram adult cells back to a stem-cell-like state — were awarded the Nobel Prize in 2012. Partial reprogramming, using these factors briefly rather than completely, has been shown to restore youthful epigenetic patterns in aged cells without erasing their identity. In animal studies, partial reprogramming has restored vision in old mice, improved muscle regeneration, and extended healthy lifespan.

Human trials are at an early stage and caution is warranted — the gap between mouse results and human outcomes is large and the safety profile is still being established. But the conceptual shift is significant. Ageing is no longer assumed to be a one-way street. The question is no longer whether biological rejuvenation is possible in principle, but how to achieve it safely and at scale.

For most people, this frontier remains years from clinical application. What it changes now is the frame. If ageing is a modifiable biological process driven by known mechanisms, then the habits that slow those mechanisms — exercise, sleep, nutrition, stress management — are not just health advice. They are, in a literal sense, interventions in the biology of ageing itself.

'Ageing used to be treated as fate. The science now treats it as a process — one with specific mechanisms, specific drivers, and specific levers. That shift changes everything about how seriously to take the basics.'

What this means practically

The hallmarks of ageing are not abstract laboratory findings. They show up in blood tests, in how quickly you recover from illness, in muscle mass, in cognitive sharpness, in how you feel at 65 compared to 55. And they respond to the same inputs that have always mattered — just with a clearer mechanistic explanation for why.

The most important practical implication is that biological age and chronological age diverge — and the divergence is largely determined by lifestyle. Studies using epigenetic clocks consistently find that people with the same chronological age can differ by a decade or more in biological age, and that the gap is explained primarily by modifiable factors. You are not simply as old as your birth certificate says. You are as old as your cells are — and that is substantially within your control.